Latham & Watkins advised Quotient Sciences, the drug development and manufacturing accelerator, on its acquisition of Arcinova, the UK based multiservice contract development and manufacturing organization. With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.

The acquisition expands Quotient’s service portfolio and will enable the integration of the drug substance, drug product and clinical testing capabilities all under one organization. Quotient is a portfolio company of private equity firm Permira. As part of the deal, Arcinova’s minority equity partner, BFG, will exit the business, having backed its growth since 2018.

Latham’s deal team was led by London corporate partners Tom Evans and Neil Campbell, with associates Cigi Puthuppally and Zaal Cama.